Movantik (naloxegol) is not a controlled substance. It was briefly classified as a Schedule II controlled substance, but the DEA formally removed it from all controlled substance schedules in January 2015. You can get Movantik with a standard prescription, and it carries none of the special prescribing restrictions that apply to controlled drugs.
Why Movantik Was Originally Scheduled
Naloxegol, the active ingredient in Movantik, was initially placed on the DEA’s Schedule II list for a straightforward technical reason: it can be chemically derived from opium alkaloids. Under the Controlled Substances Act, substances with that origin are automatically subject to the strictest controls, the same category that includes oxycodone and fentanyl.
But being derived from an opioid doesn’t mean a drug acts like one. After reviewing an eight-factor analysis and a scientific evaluation from the Department of Health and Human Services, the DEA concluded that naloxegol “does not meet the requirements for inclusion in any schedule.” The final rule removing it took effect on January 23, 2015, eliminating all regulatory controls, criminal sanctions, and administrative restrictions that had applied.
How Movantik Differs From Opioids
Movantik is actually the opposite of an opioid in how it works. It blocks opioid receptors in the gut rather than activating them, which is why it’s prescribed for opioid-induced constipation. When you take opioid pain medications, those drugs slow down your digestive system by binding to receptors in the intestinal wall. Movantik attaches to those same receptors and prevents the opioid from locking onto them, restoring more normal bowel function.
The key design feature is that Movantik stays out of the brain. The molecule has a polyethylene glycol (PEG) chain attached to it, which makes it too large and poorly absorbed to cross the blood-brain barrier effectively. In lab testing, naloxegol penetrated the central nervous system 15 times slower than naloxone, a related compound used to reverse opioid overdoses. This means Movantik relieves constipation in the gut without interfering with the pain relief your opioid provides in the brain. It has no potential for euphoria, no abuse liability, and no addictive properties.
What Movantik Is Prescribed For
Movantik is FDA-approved specifically for opioid-induced constipation in adults with chronic non-cancer pain. It belongs to a class of drugs called PAMORAs (peripherally acting mu-opioid receptor antagonists), all of which work by blocking opioid effects in the gut while leaving brain-level pain relief intact. Other drugs in this class, including Symproic (naldemedine) and Relistor (methylnaltrexone), are also not controlled substances.
The standard dose is 25 mg taken once daily in the morning. If that’s hard to tolerate, a lower 12.5 mg dose is available. People with reduced kidney function typically start at the lower dose.
Prescribing and Pharmacy Experience
Because Movantik is not a controlled substance, the prescribing process is simpler than what you may be used to with your opioid medications. Your doctor can send the prescription electronically or call it in without the special requirements that Schedule II drugs demand, like handwritten prescriptions or limits on refills. There are no DEA-related restrictions on how pharmacies store or dispense it.
That said, Movantik does carry one important contraindication worth knowing about. You cannot take it with strong CYP3A4 inhibitors, a category of drugs that includes certain antibiotics like clarithromycin and antifungal medications like ketoconazole. These drugs dramatically increase the amount of Movantik in your bloodstream, which can trigger opioid withdrawal symptoms like chills, sweating, diarrhea, abdominal pain, anxiety, and irritability. Your pharmacist will check for this interaction before dispensing.
Can Movantik Cause Withdrawal?
Even though Movantik isn’t a controlled substance and has no abuse potential, it can cause opioid withdrawal symptoms in certain situations. Because it blocks opioid receptors in the gut, some of that blocking effect can spill over if blood levels get high enough. This is most likely to happen if you take it alongside drugs that boost its concentration (the CYP3A4 inhibitors mentioned above) or at higher-than-recommended doses.
Withdrawal symptoms from Movantik are typically gastrointestinal: abdominal pain, diarrhea, nausea. These overlap with the drug’s most common side effects, so it can sometimes be difficult to tell the difference between a normal side effect and a mild withdrawal reaction. The important distinction is that these symptoms come from the drug blocking opioid receptors in your body, not from any dependency on Movantik itself. Stopping Movantik does not cause withdrawal.